182 related articles for article (PubMed ID: 36495689)
1. Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches.
Roggia C; Armeanu-Ebinger S; Gschwind A; Seibel-Kelemen O; Hertler S; Faust U; Liebmann A; Haack TB; Neumann M; Bonzheim I; Forschner A; Kopp HG; Herster F; Hartkopf A; Bitzer M; Malek NP; Brecht IB; Ruhm K; Möller Y; Löwenheim H; Ossowski S; Rieß OH; Schroeder C
Eur J Cancer; 2023 Jan; 179():48-55. PubMed ID: 36495689
[TBL] [Abstract][Full Text] [Related]
2. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations.
Kuzbari Z; Bandlamudi C; Loveday C; Garrett A; Mehine M; George A; Hanson H; Snape K; Kulkarni A; Allen S; Jezdic S; Ferrandino R; Westphalen CB; Castro E; Rodon J; Mateo J; Burghel GJ; Berger MF; Mandelker D; Turnbull C
Ann Oncol; 2023 Mar; 34(3):215-227. PubMed ID: 36529447
[TBL] [Abstract][Full Text] [Related]
3. Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine.
You YN; Borras E; Chang K; Price BA; Mork M; Chang GJ; Rodriguez-Bigas MA; Bednarski BK; Meric-Bernstam F; Vilar E
Dis Colon Rectum; 2019 Apr; 62(4):429-437. PubMed ID: 30730459
[TBL] [Abstract][Full Text] [Related]
4. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
5. Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
Van Marcke C; Helaers R; De Leener A; Merhi A; Schoonjans CA; Ambroise J; Galant C; Delrée P; Rothé F; Bar I; Khoury E; Brouillard P; Canon JL; Vuylsteke P; Machiels JP; Berlière M; Limaye N; Vikkula M; Duhoux FP
Breast Cancer Res; 2020 Apr; 22(1):36. PubMed ID: 32295625
[TBL] [Abstract][Full Text] [Related]
6. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit.
Frugtniet B; Morgan S; Murray A; Palmer-Smith S; White R; Jones R; Hanna L; Fuller C; Hudson E; Mullard A; Quinton AE
BJOG; 2022 Feb; 129(3):433-442. PubMed ID: 34657373
[TBL] [Abstract][Full Text] [Related]
7. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
Truong H; Breen K; Nandakumar S; Sjoberg DD; Kemel Y; Mehta N; Lenis AT; Reisz PA; Carruthers J; Benfante N; Joseph V; Khurram A; Gopalan A; Fine SW; Reuter VE; Vickers AJ; Birsoy O; Liu Y; Walsh M; Latham A; Mandelker D; Stadler ZK; Pietzak E; Ehdaie B; Touijer KA; Laudone VP; Slovin SF; Autio KA; Danila DC; Rathkopf DE; Eastham JA; Chen Y; Morris MJ; Offit K; Solit DB; Scher HI; Abida W; Robson ME; Carlo MI
Eur Urol; 2023 Jan; 83(1):29-38. PubMed ID: 36115772
[TBL] [Abstract][Full Text] [Related]
8. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
Mandelker D; Donoghue M; Talukdar S; Bandlamudi C; Srinivasan P; Vivek M; Jezdic S; Hanson H; Snape K; Kulkarni A; Hawkes L; Douillard JY; Wallace SE; Rial-Sebbag E; Meric-Bersntam F; George A; Chubb D; Loveday C; Ladanyi M; Berger MF; Taylor BS; Turnbull C
Ann Oncol; 2019 Aug; 30(8):1221-1231. PubMed ID: 31050713
[TBL] [Abstract][Full Text] [Related]
9. Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma.
Goebel EA; Kerkhof J; Dzyubak O; McLachlin CM; McGee J; Sadikovic B
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011309
[TBL] [Abstract][Full Text] [Related]
10. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
11. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
[TBL] [Abstract][Full Text] [Related]
12. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
13. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.
DiNardo CD; Routbort MJ; Bannon SA; Benton CB; Takahashi K; Kornblau SM; Luthra R; Kanagal-Shamanna R; Medeiros LJ; Garcia-Manero G; M Kantarjian H; Futreal PA; Meric-Bernstam F; Patel KP
Cancer; 2018 Jul; 124(13):2704-2713. PubMed ID: 29682723
[TBL] [Abstract][Full Text] [Related]
14. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
[TBL] [Abstract][Full Text] [Related]
16. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
17. Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.
Carlo MI; Ravichandran V; Srinavasan P; Bandlamudi C; Kemel Y; Ceyhan-Birsoy O; Mukherjee S; Mandelker D; Chaim J; Knezevic A; Rana S; Fnu Z; Breen K; Arnold AG; Khurram A; Tkachuk K; Cipolla CK; Regazzi A; Hakimi AA; Al-Ahmadie H; Dalbagni G; Cadoo KA; Walsh MF; Teo MY; Funt SA; Coleman JA; Bochner BH; Iyer G; Solit DB; Stadler ZK; Zhang L; Rosenberg JE; Taylor BS; Robson ME; Berger MF; Vijai J; Bajorin DF; Offit K
J Clin Oncol; 2020 Feb; 38(5):406-414. PubMed ID: 31794323
[TBL] [Abstract][Full Text] [Related]
18. The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.
McVeigh TP; Sundar R; Diamantis N; Kaye SB; Banerji U; Lopez JS; de Bono J; van der Graaf WTA; George AJ
Eur J Cancer; 2018 May; 95():20-29. PubMed ID: 29614442
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.
Jahn A; Rump A; Widmann TJ; Heining C; Horak P; Hutter B; Paramasivam N; Uhrig S; Gieldon L; Drukewitz S; Kübler A; Bermudez M; Hackmann K; Porrmann J; Wagner J; Arlt M; Franke M; Fischer J; Kowalzyk Z; William D; Weth V; Oster S; Fröhlich M; Hüllein J; Valle González C; Kreutzfeldt S; Mock A; Heilig CE; Lipka DB; Möhrmann L; Hanf D; Oleś M; Teleanu V; Allgäuer M; Ruhnke L; Kutz O; Knurr A; Laßmann A; Endris V; Neumann O; Penzel R; Beck K; Richter D; Winter U; Wolf S; Pfütze K; Geörg C; Meißburger B; Buchhalter I; Augustin M; Aulitzky WE; Hohenberger P; Kroiss M; Schirmacher P; Schlenk RF; Keilholz U; Klauschen F; Folprecht G; Bauer S; Siveke JT; Brandts CH; Kindler T; Boerries M; Illert AL; von Bubnoff N; Jost PJ; Metzeler KH; Bitzer M; Schulze-Osthoff K; von Kalle C; Brors B; Stenzinger A; Weichert W; Hübschmann D; Fröhling S; Glimm H; Schröck E; Klink B
Ann Oncol; 2022 Nov; 33(11):1186-1199. PubMed ID: 35988656
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.
Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L
BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
